Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com

Articles

Subsequent Therapy Shows No Difference in OS Following IO/TKI-Based Treatment in RCC

August 19th 2024

Neil J. Shah, MBBS, discusses real-world outcomes of patients with metastatic RCC receiving treatment in the post-IO/TKI setting following progression.

Retrospective Study Exemplifies the Environmental and Health Impacts of Decentralizing Cancer Care

August 18th 2024

Andrew Hantel, MD, discusses environmental and health impacts of decentralizing cancer care in response to high emissions generated by US health care.

Potentially Modifiable Eligibility Criteria Drive Enrollment Disparities in AML Clinical Trials

August 16th 2024

Andrew Hantel, MD, discusses the evaluation of eligibility criteria in acute myeloid leukemia clinical trials that may perpetuate racial disparities.

FDA Grants Priority Review to Vimseltinib in Tenosynovial Giant Cell Tumor

August 16th 2024

The FDA has accepted an NDA for vimseltinib for the treatment of patients with tenosynovial giant cell tumor, with a PDUFA date of February 17, 2025.

Time to Next Therapy Demonstrates Potential as an Intermediate End Point in Metastatic RCC

August 16th 2024

Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.

Linvoseltamab Demonstrates Deep, Durable Responses in R/R Myeloma Ahead of FDA Action Date

August 15th 2024

Suzanne Lentzsch, MD, PhD, discusses updated data from the LINKER-MM1 study of linvoseltamab in relapsed/refractory multiple myeloma.

Targeted Therapy Combinations Could Represent Next Wave of Treatments in Follicular Lymphoma

August 15th 2024

Geoffrey Shouse, DO, PhD, discusses the benefits of utilizing targeted therapy approaches in the treatment of patients with follicular lymphoma.

China’s NMPA Grants Breakthrough Therapy Designation to 9MW2821 in Advanced Urothelial Cancer

August 12th 2024

The Nectin-4–directed antibody-drug conjugate 9MW2821 has received breakthrough therapy designation in China for pretreated, advanced urothelial carcinoma.

Rhenium Obisbemeda Demonstrates Safety and Feasibility in Leptomeningeal Metastases

August 12th 2024

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

T-Cell Therapy Deltacel Elicits Early Safety and Efficacy in NSCLC

August 9th 2024

Deltacel generated early signals of clinical efficacy in patients with metastatic non–small cell lung cancer who have not responded to standard therapies.

Observational REVEAL Study Highlights Potential Risk Factors for Disease Transformation in Polycythemia Vera

August 9th 2024

Michael R. Grunwald, MD, discusses findings from a real-world observational study of risk factors related to disease progression in polycythemia vera.

Dr Bazhenova on Updated Data From the TRUST-I Trial of Taletrectinib in ROS1+ NSCLC

August 8th 2024

Lyudmila A. Bazhenova, MD, discusses updated efficacy data from the TRUST-I study of taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Olomorasib Plus Pembrolizumab Generates Antitumor Activity in KRAS G12C+ NSCLC

August 8th 2024

Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.

Pacritinib Demonstrates Safety in Solid Tumors Harboring 1q21.3 Amplifications

August 8th 2024

Pacritinib was tolerable with a reasonable safety profile in patients with solid tumors harboring 1q21.3 copy number amplifications.

Chemotherapy-Free Approaches Are at the Forefront in MCL

August 5th 2024

Alexey Danilov, MD, PhD, highlights non-chemotherapy options for the treatment of mantle cell lymphoma and expands on ongoing research in hematologic malignancies.

Suvemcitug Plus Chemo Boost PFS in Platinum-Resistant Ovarian Cancer

August 4th 2024

Suvemcitug plus chemotherapy improved progression-free survival in platinum-resistant ovarian cancer.

Ceralasertib/Olaparib is Active in Recurrent, Platinum-Sensitive, Recurrent Ovarian Cancer Irrespective of HRD Status

August 3rd 2024

Ceralasertib plus olaparib demonstrated clinical activity in platinum-sensitive, recurrent, high-grade serous ovarian cancer, regardless of HRD status.

BTK Degraders and Fixed-Duration Regimens May Represent the Future in CLL

August 2nd 2024

Alexey Danilov, MD, PhD, highlights the evolution of targeting BTK, sharing new data on BTK degraders and more in chronic lymphocytic leukemia

Revisit Every OncLive On Air Episode From July 2024

July 31st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

Ongoing Research Aims to Bring Novel TROP-2–Directed ADCs to Metastatic TNBC

July 31st 2024

Sara M. Tolaney, MD, MPH, discusses the ongoing investigation of TROP-2–directed antibody-drug conjugates in triple-negative breast cancer.